首页> 美国卫生研究院文献>Springer Open Choice >Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

【2h】

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

机译：循环蛋白在未治疗的转移性肾细胞癌患者中作为舒尼替尼和干扰素-α疗效的潜在生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose We investigated potential biomarkers of efficacy in a phase III trial of sunitinib versus interferon-alpha (IFN-α), first-line in metastatic renal cell carcinoma (mRCC), by analyzing plasma levels of vascular endothelial growth factor (VEGF)-A, VEGF-C, soluble VEGF receptor-3 (sVEGFR-3) and interleukin (IL)-8.

机译：目的我们通过分析血浆血管内皮生长因子（VEGF）-A水平，研究了舒尼替尼与干扰素-α（IFN-α）一线治疗转移性肾细胞癌（mRCC）的III期临床试验中可能的功效生物标志物。，VEGF-C，可溶性VEGF受体3（sVEGFR-3）和白介素（IL）-8。

著录项

期刊名称 Springer Open Choice
作者
Charles S. Harmon; Samuel E. DePrimo; Robert A. Figlin; Gary R. Hudes; Thomas E. Hutson; M. Dror Michaelson; Sylvie Négrier; Sindy T. Kim; Xin Huang; J. Andrew Williams; Tim Eisen; Robert J. Motzer;
展开▼
作者单位

展开▼
年(卷),期 -1(73),1
年度 -1
页码 151–161
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词
Metastatic renal cell carcinoma Sunitinib Biomarkers Phase III clinical trial;

机译：转移性肾细胞癌;舒尼替尼;生物标志物;III期临床试验;

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-na?ve patients with metastatic renal cell carcinoma [J] . HarmonC.S., DeprimoS.E., FiglinR.A., Cancer chemotherapy and pharmacology. . 2014,第1期

机译：循环蛋白作为舒尼替尼和干扰素-α在潜在的初治转移性肾细胞癌患者中的潜在生物标志物
3. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [J] . Samuel E DePrimo, Carlo L Bello, John Smeraglia, Journal of Translational Medicine . 2007,第1期

机译：舒尼替尼在转移性肾细胞癌患者中药理活性的循环蛋白生物标志物：VEGF和VEGF相关蛋白的调节
4. Investigation of novel circulating proteins, germ.lineMngle-nii^leoticle.polymorphisms, and molecular tumor markers as- potential efficacy biomarkers of first-line sunitinib therapy for advanced renal-cell carcinoma [J] . Eobert J. Motzer, Thomas E. Hutson, Gary R. Hudes, Cancer chemotherapy and pharmacology. . 2014,第4期

机译：舒尼替尼一线治疗晚期肾细胞癌的新型循环蛋白，种系Mngle-nilelelelele，多态性和分子肿瘤标志物作为潜在疗效生物标志物的研究
5. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
6. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
7. Investigation of novel circulating proteins germ line single-nucleotide polymorphisms and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma [O] . Robert J. Motzer, Thomas E. Hutson, Gary R. Hudes, -1

机译：研究新型循环蛋白种系单核苷酸多态性和分子肿瘤标志物作为一线舒尼替尼治疗晚期肾细胞癌的潜在功效生物标志物
8. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma [O] . Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, 2013

机译：循环蛋白在未治疗的转移性肾细胞癌患者中作为舒尼替尼和干扰素-α疗效的潜在生物标志物

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅